



Announcement

Gene Expression is now published by Xia & He Publishing Inc.



The Editorial Office of *Gene Expression*

Received: September 13, 2022 | Revised: September 25, 2022 | Accepted: September 28, 2022 | Published: September 28, 2022

We are excited to announce that, from the September 2022 issue, Xia & He Publishing Inc. will continue to publish *Gene Expression* (GE).

GE, ISSN 1555-3884,¹ was launched in 1991 by Chicago Medical School Press and transferred to Cognizant Communication Corporation in 1994.² The primary research topics included cell biology, molecular biology, genes, genetics, and internal medicine. Over the past three decades, GE has published 20 volumes with 90 issues and over 600 papers and has become a reputable journal.³ It is currently indexed by Medline, PubMed, Scopus, Biosis Previews, and many other databases. The latest CiteScore released by Scopus in June 2022 is 10.8, ranking the journal in the tier 1 group in both genetics and molecular biology categories.⁴

Xia & He Publishing Inc., an emerging internationally recognized publisher focusing on publishing biomedical journals, is proud of and confident in continuing publication of GE and will make every effort to maintain and enhance the journal's quality. GE keeps its focus and scope on publishing high-impact original and review articles, editorials, commentaries, and opinions, especially on the cellular and molecular mechanisms of liver diseases. The editorial policies, such as the single-blind peer review process, final decision-making by Editors-in-Chief/Senior Editors for all manuscripts, and the open access model are also continued.

There will be several enhancements in the publishing practices under the new publisher. First, the ScholarOne manuscript system will be used to process online submissions, ensuring high effi-

ciency and international standards of the manuscript processing. Second, the journal will be published regularly and will become a quarterly journal starting from 2023. Third, the new website provides explicit guidelines for authors and reviewers and ethical statements. Fourth, the journal switches to a new PDF style for all published articles to make them more readable. Fifth, GE will remain an open-access international journal, and will waive the article processing charge for 2022 and 2023.

We want to take this opportunity to thank Cognizant Communication Corporation for having built GE into a mature journal. We wish to extend our gratitude to the previous and existing editors-in-chief, senior editors, associate editors, editorial board members, authors, reviewers, and readers for their previous and continuous contributions and support to the journal.

References

- [1] ISSN Portal. Available from: <https://portal.issn.org/resource/ISSN/1555-3884>. Accessed September 26, 2022.
- [2] National Library of Medicine. Available from: <https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Gene+Expr%22%5BTitle+Abbreviation%5D>. Accessed September 26, 2022.
- [3] PubMed Central. Gene Expression. Available from: <https://www.ncbi.nlm.nih.gov/pmc/journals/3221/>. Accessed September 21, 2022.
- [4] Scopus. Available from: <https://www.scopus.com/sourceid/22120>. Accessed September 26, 2022.